Aside from better awareness, this allows earlier interventions, though these still need to be validated. In practice, the questionnaire may be useful in assessing whether individual patients are at higher risk of NA due to specific adherence barriers. The ABQ-IVT is a practical and reliable instrument for identifying patient-specific barriers to IVT treatment adherence.
Cluster analysis identified six patient subpopulations, each affected by different sets of barriers and differed regarding their patient characteristics. The most frequently reported barriers were “Challenge due to time commitment of physician visits” (45% of the patients), “Depression” (29%) and “Travel and opportunity costs” (27%). On average, a patient was affected by 3.1 barriers. Nearly half of the patients (49%) reported being affected by at least three different barriers. The condensed questionnaire demonstrated good internal consistency (Cronbach’s alpha = 0.78), and factor analysis showed no evidence for subscales of the questionnaire. Within the reliability analysis, the ABQ-IVT was reduced to 17 items. Of 253 patients, 234 (92%) were able to complete the ABQ-IVT questionnaire. Patients’ answers to the ABQ-IVT questionnaire and interviews. Due to difficulties in capturing NA as an external criterion, the evaluation of the questionnaire was limited to its internal validity and reliability. To identify patient subpopulations, hierarchical cluster analysis was performed using ABQ-IVT answers as predictors. The occurrence of potential barriers in the patient sample was evaluated using descriptive statistics. Evaluation of the questionnaire included an assessment of internal consistency and factor analysis. The ABQ-IVT, which initially consisted of 24 items formulated as statements (4-point-Likert-scale ranging from “strongly agree” to “strongly disagree”), was applied in a cross-sectional survey.
The previously validated (indications: atrial fibrillation, human immunodeficiency virus, chronic inflammatory lung disease) Adherence Barriers Questionnaire (ABQ) was revised according to specifications of IVT, within the framework of an expert panel. German patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) receiving anti-vascular endothelial growth factor (anti-VEGF) treatment via IVT. Questionnaire development and cross-sectional patient survey combined with a retrospective medical chart review. To develop and validate a questionnaire for the investigation of non-adherence (NA) barriers in patients receiving intravitreal injection (IVT).
0 kommentar(er)
